載入中
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
最新資料
US$2.46
+US$0.04 · +1.65%
盤中時間採用ET。市場資料可能有所延遲。
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 62.60%價格歷史記錄不可用
最高：US$5.00平均的：US$4.00最低：US$3.00年度分割調整後的每股現金分配。
US$0.27
2013年（完整年度）+35.0% 自從 2010
US$0.20
2,010
US$0.20
2,011
US$0.23
2,012
US$0.27
2,013
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2014年4月28日 | US$0.07Quarterly | 2014年4月30日 | 2014年5月7日 |
股息 | 2014年1月27日 | US$0.07Quarterly | 2014年1月29日 | 2014年2月5日 |
股息 | 2013年10月28日 | US$0.07Quarterly | 2013年10月30日 | 2013年11月6日 |
股息 | 2013年7月29日 | US$0.07Quarterly | 2013年7月31日 | 2013年8月7日 |
股息 | 2013年4月29日 | US$0.07Quarterly | 2013年5月1日 | 2013年5月8日 |
股息 | 2013年1月28日 | US$0.06Quarterly | 2013年1月30日 | 2013年2月6日 |
除息 2014年4月28日
US$0.07
Quarterly
2014年4月30日登記 · 支付日 2014年5月7日
除息 2014年1月27日
US$0.07
Quarterly
2014年1月29日登記 · 支付日 2014年2月5日
除息 2013年10月28日
US$0.07
Quarterly
2013年10月30日登記 · 支付日 2013年11月6日
除息 2013年7月29日
US$0.07
Quarterly
2013年7月31日登記 · 支付日 2013年8月7日
除息 2013年4月29日
US$0.07
Quarterly
2013年5月1日登記 · 支付日 2013年5月8日
除息 2013年1月28日
US$0.06
Quarterly
2013年1月30日登記 · 支付日 2013年2月6日
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
